IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The firm develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The firm is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.
IO Biotech Inc 주요 수익원은 Payment Processing and Digital Banking Technologies이며, 최신 수익 발표에서 수익은 276,000입니다. 지역별로는 United States이 IO Biotech Inc의 주요 시장이며, 수익은 276,000입니다.